Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Accelrys, Inc. (“Accelrys” or the “Company”) (Nasdaq:ACCL) relating to the acquisition by Dassault Systems SA (“Dassault”). Click here to learn more about the investigation http://brodsky-smith.com/716-accl-accelrys-inc.html, or call: 877-534-2590. There is no cost or obligation to you. Under the terms of the transaction, Accelrys shareholders will receive only $12.50 in cash for each share of Accelrys stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Accelrys for not acting in the Company’s shareholders’ best interests in connection with the sale process. The transaction may undervalue the Company as the transaction will allow Dassault access to both the Company’s impressive client list and the proprietary software used in chemical and biological product life cycle management. In addition, an analyst has set a $13.00 per share price target on Accelrys stock. If you own shares of Accelrys common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at firstname.lastname@example.org, by visiting http://brodsky-smith.com/716-accl-accelrys-inc.html, or calling toll free 877-LEGAL-90. Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.